A RECRUITMENT campaign has begun for participants in a Phase 2A clinical trial of a combination medicine for treatment of depression, developed by ASX-listed Medlab Clinical.
Phase I studies showed the combination of Medlab's NRGBiotic "probiotic neutraceutical" with a selective serotonin reuptake inhibitor (SSRI), afforded "significant patient improvement".
The Phase 2a study is designed to strengthen those initial findings in a wider group of patients, with the recruitment campaign intended to enrol 150 people diagnosed with depression, with progressive implementation of the trial as recruitment continues.
The trial is a collaboration between Medlab, Queenland University and Qld University of Technology (QUT), which is running the patient recruitment campaign.
Principal investigator of the trial will be QUT's Dr Esben Strodl, senior lecturer in the School of Psychology and Counselling, QUT Institute of Health and Biomedical Innovation.
Trial design is also intended to meet requirements of a new expedited drug approval mechanism being developed by the Therapeutic Goods Administration to provide faster access to new medicines with community benefit.
More information on the trial is available at qut.edu.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Jul 18
